Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
Paris, October 30, 2021 – Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, has been awarded the prix Galien Medstartup Award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY” for its collaboration with Pr James Grotta at the Memorial Hermann Hospital, TX.
This collaboration aims to prepare an international clinical trial ACTISAVE to evaluate the efficacy of glenzocimab in patients suffering from acute ischemic stroke. ACTISAVE (NCT05070260) will be an adaptive phase 2/3, multinational, randomized, double-blind, multicenter, placebo-controlled, parallel group, single dose, efficacy and safety study of glenzocimab used as an add-on to standard of care therapy for acute ischemic stroke.
“This joint recognition marks the milestones we have reached in our work on glenzocimab to treat the acute phase of ischemic stroke, and it highlights the importance of close collaboration between a sponsor and clinical experts.” Commented Gilles Avenard, CEO of Acticor Biotech.
|SUCCES DE LA PREMIERE OPERATION DE RECONSTRUCTION MAMMAIRE AVEC MATTISSE 🚀|
Le 12 juillet 2022, une première patiente atteinte d’un cancer du sein a pu bénéficier d’une reconstruction mammaire grâce à notre implant #MATTISSE.
Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.
After taking Vik Atopic Dermatitis to 9 countries and in four different languages, our main goal remains guiding patients through their search for a healthier life.
Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today.